

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 2

**CLAIM AMENDMENTS**

Claims 1-244 are cancelled.

245. (Currently Amended) A multimeric complex composition comprising more than one

monomeric unit, said monomeric unit comprising a compound and polymer and wherein said monomeric units are attached

- (a) to each other through noncovalent polymeric interactions of the polymers of the monomeric units, or
- ~~(b) to a binding matrix comprising a polymer through noncovalent polymeric interactions between said polymer of said monomeric unit and said polymer of said binding matrix, or~~
- ~~(c) both (a) and (b).~~

246. (previously presented) The composition of claim 245, wherein the polymer or oligomer of said monomeric unit is linear or branched.

247. (previously presented) The composition of claim 245, wherein the polymer or oligomer of said monomeric unit comprises of homopolymer or heteropolymer.

248. (previously presented) The composition of claim 245, wherein said monomeric unit comprises an analyte-specific moiety.

249. (previously presented) The composition of claim 248, wherein said analyte-specific moiety is capable of recognizing a component in a biological system.

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 3

250. (previously presented) The composition of claim 249, wherein said biological system is selected from a virus, a phage, a bacterium, a cell or cellular material, a tissue, an organ and an organism, or a combination thereof.

251. (previously presented) The composition of claim 245, wherein said monomeric unit is selected from a naturally occurring compound, a modified natural compound, a synthetic compound and a recombinantly produced compound, or a combination thereof.

252. (currently amended) The composition of claim 245~~248~~, wherein said analyte-specific moiety is derived or selected from a protein, a polysaccharide, a fatty acid or fatty acid ester and a polynucleotide, or a combination of the foregoing.

253. (previously amended) The composition of claim 252, wherein said protein is selected from an antibody, a hormone, a growth factor, a lymphokine or cytokine a cellular matrix protein, receptor binding protein or a combination of any of the foregoing.

254. (withdrawn) The composition of claim 253, wherein said antibody comprises a polyclonal or monoclonal antibody.

255. (previously presented) The composition of claim 252, wherein said polynucleotide is linear or circular.

256. (previously presented) The composition of claim 252, wherein said polynucleotide is single stranded.

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 4

257. (previously presented) The composition of claim 245, wherein the polymer or oligomer of said binding matrix is linear or branched.

258. (previously presented) The composition of claim 245, wherein the polymer or oligomer of said binding matrix comprises a homopolymer or heteropolymer.

259. (previously presented) The composition of claim 245, wherein said binding matrix from a naturally occurring compound, a modified natural compound, a synthetic compound and a recombinantly produced compound, or a combination thereof.

260. (previously presented) The composition of claim 245, wherein said binding matrix comprises a member selected from a polypeptide, a polynucleotide and a polysaccharide, or a combination thereof.

261. (previously presented) The composition of claim 245, wherein said polymeric interactions are selected from ionic interactions, hydrogen bonding, dipole-dipole interactions, or a combination of the foregoing

262. (previously amended) The composition of claim 261, wherein said ionic interactions comprise polycationic interactions polyanionic interactions or combination of polycationic and anionic interactions.

263. (previously presented) The composition of claim 245, further comprising an entity attached to said binding matrix.

264. (previously presented) The composition of claim 263, wherein said entity comprises a ligand or a compound which increases binding of the binding matrix.

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 5

265. (withdrawn) The composition of claim 245, in homogeneous form.

266. (previously presented) The composition of claim 245, in heterogeneous form.

267. (previously presented) A process for delivering a cell effector to a cell, comprising: providing the multimeric complex composition of claim 245 wherein said monomeric unit comprises said cell effector; and administering said composition.

268. (previously presented) The process of claim 267, wherein said composition is delivered in vivo.

269. (previously presented) The process of claim 267, wherein said composition is delivered ex vivo.

270. (previously presented) The process of claim 267, wherein said cell is contained in an organism.

271. (previously presented) A process for delivering a gene or fragment thereof to a cell, comprising: providing the multimeric complex composition of claim 245, wherein said monomeric unit comprises said gene or gene fragment; and administering said composition.

272. (previously presented) The process of claim 271, wherein said composition is delivered in vivo.

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 6

273. (previously presented) The process of claim 271, wherein said composition is delivered ex vivo.

274. (previously presented) The process of claim 271, wherein said cell is contained in an organism.

275. (currently amended) A multimeric composition comprising more than one component attached noncovalently to a charged polymer, wherein said charged polymer is selected from a polycationic polymer, a polyionic polymer, a polynucleotide, a modified polynucleotide and a polynucleotide analog, or a combination of the foregoing monomeric unit, said monomeric unit comprising a compound and polymer and wherein said monomeric units are attached to a binding matrix comprising a polymer through noncovalent polymeric interactions selected from the group consisting of hydrogen bonding and dipole interactions and combinations thereof, between said polymer of said monomeric unit and said polymer of said binding matrix.

276. (currently amended) The multimeric composition of claim 275, wherein said component compound comprises a protein.

277. (previously presented) The multimeric composition of claim 276, wherein said protein is selected from an antibody and an F(ab')z fragment, or both.

278. (withdrawn) The multimeric composition of claim 277, wherein said antibody comprises a polyclonal or monoclonal antibody.

279. (withdrawn) The multimeric composition of claim 277, wherein said antibody is further complex with a target comprising an enzyme.

Rabbani et al.  
Serial No.: 08/978,634  
Filed: November 25, 1997  
Page 7

280. (previously presented) The composition of claim 245, wherein said monomeric unit contains polycationic segments and the binding matrix contains polyanionic segments.

281. (previously presented) The composition of claim 245, wherein said monomeric unit contains polyanionic segments and the binding matrix contains polycationic segments.

282. (new) The composition of claim 245, wherein said monomeric units are also attached to a binding matrix comprising a polymer through noncovalent polymeric interactions between said polymer of said monomeric unit and said polymer of said binding matrix.

283. (new) The composition of claim 275, wherein more than one compound is attached to a polymer.